Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of Oncoxin, a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma

Trial Profile

Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of Oncoxin, a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Arginine/ascorbic-acid/cinnamic-acid/cysteine/epigallocatechin-gallate/magnesium-sulfate/pyridoxine/repagermanium/zinc-sulfate (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top